

03-29-01

A/Box/seq

**UTILITY PATENT APPLICATION TRANSMITTAL  
(Small Entity)**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
31508Total Pages in this Submission  
51**TO THE ASSISTANT COMMISSIONER FOR PATENTS**Box Patent Application  
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

**CANCER CELL-SPECIFIC HLA-F ANTIGEN AND A DIAGNOSTIC METHOD OF CANCER BY USING THEREOF**

and invented by:

**KOHJI EGAWA**JC918 U.S. PTO  
09/819371  
03/28/01If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_

Enclosed are:

**Application Elements**

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 30 pages and including the following:
  - a. ☒ Descriptive Title of the Invention
  - b. ☐ Cross References to Related Applications (if applicable)
  - c. ☐ Statement Regarding Federally-sponsored Research/Development (if applicable)
  - d. ☐ Reference to Microfiche Appendix (if applicable)
  - e. ☒ Background of the Invention
  - f. ☒ Brief Summary of the Invention
  - g. ☐ Brief Description of the Drawings (if drawings filed)
  - h. ☒ Detailed Description
  - i. ☒ Claim(s) as Classified Below
  - j. ☒ Abstract of the Disclosure

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Small Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.  
**31508**

Total Pages in this Submission  
**51**

**Application Elements (Continued)**

3. ☐ Drawing(s) *(when necessary as prescribed by 35 USC 113)*  
a. ☐ Formal      b. ☐ Informal      Number of Sheets \_\_\_\_\_
4. ☒ Oath or Declaration  
a. ☒ Newly executed *(original or copy)*      ☐ Unexecuted  
b. ☐ Copy from a prior application (37 CFR 1.63(d)) *(for continuation/divisional application only)*  
c. ☒ With Power of Attorney      ☐ Without Power of Attorney  
d. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application,  
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference *(usable if Box 4b is checked)*  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under  
Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby  
incorporated by reference therein.
6. ☐ Computer Program in Microfiche
7. ☒ Genetic Sequence Submission *(if applicable, all must be included)*  
a. ☒ Paper Copy  
b. ☒ Computer Readable Copy  
c. ☒ Statement Verifying Identical Paper and Computer Readable Copy

**Accompanying Application Parts**

8. ☒ Assignment Papers *(cover sheet & documents)*
9. ☐ 37 CFR 3.73(b) Statement *(when there is an assignee)*
10. ☐ English Translation Document *(if applicable)*
11. ☐ Information Disclosure Statement/PTO-1449      ☐ Copies of IDS Citations
12. ☒ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing  
☐ First Class      ☒ Express Mail *(Specify Label No.):* **EL759816504US**

**UTILITY PATENT APPLICATION TRANSMITTAL  
(Small Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.  
**31508**

Total Pages in this Submission  
**51**

**Accompanying Application Parts (Continued)**

15. ☐ Certified Copy of Priority Document(s) *(if foreign priority is claimed)*
16. ☐ Small Entity Statement(s) - Specify Number of Statements Submitted: \_\_\_\_\_
17. ☐ Additional Enclosures *(please identify below)*:

**Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)**

18. ☐ Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

**Warning**

***An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.***

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Small Entity)**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
**31508**

Total Pages in this Submission  
**51**

**Fee Calculation and Transmittal**

**CLAIMS AS FILED**

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	25	- 20 =	5	x \$9.00	\$45.00
Indep. Claims	5	- 3 =	2	x \$40.00	\$80.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$355.00
OTHER FEE (specify purpose) _____					\$0.00
TOTAL FILING FEE					\$480.00

- ☒ A check in the amount of **\$480.00** to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. **19-0522** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_ as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: **28 March 2001**

  
Signature  
Tracey S. Truitt, Reg. No. 43,205



**23589**

PATENT TRADEMARK OFFICE

CC:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

EGAWA, KOHJI

Serial No. :


Filed:

CANCER CELL-SPECIFIC HLA-F  
ANTIGEN AND A DIAGNOSTIC  
METHOD OF CANCER BY USING  
THEREOF

Docket No. 31508

Group Art Unit No.

Examiner:



Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

**TRANSMITTAL LETTER**

Transmitted herewith are two CD-Rs ("compact disks-write once") labeled and hereafter referred to as Copy 1 and Copy 2.

Copy 1 and Copy 2 each contain an identical copy of a sequence listing appendix associated with and incorporated by reference into the above-identified non-provisional utility application. The machine format of each CD-R is IBM-PC; and the operating system compatibility is Windows 95.

Copy 1 and Copy 2 each contain identical copies of the following ASCII files:

Filename	Size (Bytes)	Date of Creation
30518S~1.TXT	11 kb	3/28/2001

Respectfully submitted,

By

A handwritten signature in black ink, appearing to read "Tracey S. Truitt", written over a horizontal line.

Tracey S. Truitt, Reg. No. 43,205  
2405 Grand Boulevard, Suite 400  
Kansas City MO 64108  
(816) 474-9050

ATTORNEY FOR APPLICANT(S)

09/819371-032801

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)**

Applicant(s): EGAWA, KOHJI

Docket No.  
31508

Serial No.

Filing Date

Examiner

Group Art Unit

Invention: CANCER CELL-SPECIFIC HLA-F ANTIGEN AND A DIAGNOSTIC METHOD OF  
CANCER BY USING THEREOF

I hereby certify that this Express Mail Certification; Patent Transmittal Letter (Small Entity); Application for U.S. Letters Patent including specification, claims and abstract page (30 pgs); Sequence Listing (6 pages); \$480.00 Filing Fee; Preliminary Amendment; Rule 1.821(f) Statement; Transmittal Letter; 2 copies of CD-Rs; Combined Declaration and Power of Attorney (signed); Assignment including transmittal sheet (3 pgs) with \$40.00 recordation fee; are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on March 28, 2001.

Penelope Kre

(Typed or Printed Name of person Mailing Correspondence)




(Signature of Person Mailing Correspondence)

EL759816504US

("Express Mail" Mailing Label Number)

JC918 U.S. PTO

09/819371



03/28/01

SCANNED. # 2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

EGAWA, KOHJI

Serial No. :

Filed:

CANCER CELL-SPECIFIC HLA-F  
ANTIGEN AND A DIAGNOSTIC  
METHOD OF CANCER BY USING  
THEREOF

Group Art Unit No.

Examiner:

Box SEQ  
Assistant Commissioner of Patents  
Washington, D.C. 20231


Sir:

STATEMENT

Rule 1.821(f) requires a Statement to the effect that the contents of the Sequence Listing and the Computer Readable Form are the same. Such is the case for the Sequence Listing and the Computer Readable Form that accompany this Statement.

Respectfully submitted,

By

  
Tracey S. Truitt, Reg. No. 43,205  
2405 Grand Boulevard, Suite 400  
Kansas City, Missouri 64108  
816/474-9050

ATTORNEYS FOR APPLICANT(S)

(Docket No. 31508)

09819371-032801  
108260 T 45 TB50